Study guide
Behavioral health is a well-represented content area on Step 2 CK, testing recognition of psychiatric emergencies, accurate application of DSM-5-TR diagnostic criteria to distinguish overlapping mood/psychotic disorders, and evidence-based psychopharmacology including management of treatment-resistant conditions and substance use disorders. Safety assessment and disposition decisions (hospitalization vs. outpatient follow-up) are a recurring theme throughout this chapter.
Suicide Risk Assessment and Management
Suicide risk assessment vignettes test a structured approach: eliciting suicidal ideation directly (asking about it does not increase risk), assessing for a specific plan, access to lethal means (particularly firearms), intent, and protective factors, then using this information to determine the appropriate level of care. Patients with active suicidal ideation, a specific plan, and access to means generally require involuntary or voluntary psychiatric hospitalization for safety, even against the patient's wishes if they lack capacity to keep themselves safe, since immediate safety supersedes typical consent and confidentiality norms in this emergency context. Removing access to lethal means (asking family to secure or remove firearms and medications) is a key concrete intervention. Chronic passive ideation without plan or intent in a patient with strong protective factors and outpatient support may be manageable with close outpatient follow-up rather than hospitalization, but vignettes test recognizing when risk factors escalate the required level of care. Step 2 CK emphasizes that clinicians must directly and specifically ask about suicidal ideation, plan, and means in any patient with depressive symptoms or risk factors, since failure to assess is itself a tested error, and that safety takes precedence over other considerations such as insurance status or patient reluctance to be hospitalized. Written no-suicide safety contracts have no demonstrated protective efficacy and should not substitute for hospitalization in a high-risk patient.
Differentiating Psychotic and Mood Disorders
Step 2 CK tests precise application of DSM-5-TR criteria to distinguish overlapping psychotic and mood disorders based on the temporal relationship between mood episodes and psychotic symptoms. Schizophrenia requires psychotic symptoms (delusions, hallucinations, disorganized speech/behavior, negative symptoms) for a specified duration with functional decline, without a mood component that occupies the majority of the illness course. Schizoaffective disorder requires an uninterrupted period of illness with a major mood episode (depressive or manic) concurrent with the psychotic criteria for schizophrenia, but critically also requires psychotic symptoms (delusions or hallucinations) for at least two weeks in the absence of a mood episode at some point in the illness, with mood symptoms present for the majority of the total illness duration — this distinguishes it from a mood disorder with psychotic features, where psychotic symptoms occur exclusively during mood episodes. Brief psychotic disorder and schizophreniform disorder are distinguished from schizophrenia primarily by symptom duration (brief psychotic disorder more than 1 day but under one month with full return to baseline, schizophreniform disorder one to six months, schizophrenia requiring six months or more of continuous signs). Vignettes reward carefully tracking the timeline given in the stem (when did mood symptoms start relative to psychosis, and did psychosis ever occur without mood symptoms) rather than pattern-matching on symptom checklists alone.
Psychopharmacology and Treatment-Resistant Schizophrenia
Treatment-resistant schizophrenia is defined as inadequate response to trials of at least two antipsychotic medications at adequate dose and duration with confirmed adherence (typically from different classes), and the guideline-supported next step is clozapine, the most effective agent for treatment-resistant psychosis, though its use requires mandatory regular absolute neutrophil count monitoring due to the risk of agranulocytosis, along with monitoring for other adverse effects such as metabolic syndrome, myocarditis, and seizures at higher doses. Step 2 CK tests recognizing when a vignette describes true treatment resistance (adequate trials of multiple agents with confirmed adherence, not simply one failed medication or nonadherence) as the trigger for initiating clozapine rather than simply switching to another standard antipsychotic. General antipsychotic pharmacology testing includes distinguishing first-generation (typical) antipsychotics, with higher risk of extrapyramidal symptoms and tardive dyskinesia, from second-generation (atypical) antipsychotics, with higher metabolic risk (weight gain, dyslipidemia, diabetes); recognizing and managing neuroleptic malignant syndrome (fever, rigidity, autonomic instability, elevated creatine kinase) as an emergency requiring drug discontinuation, cooling, and supportive care (with dantrolene or bromocriptine in severe cases) is also a core tested topic within this domain.
Substance Use Disorders: Opioid Use Disorder Treatment
Opioid use disorder management on Step 2 CK centers on recognizing withdrawal versus intoxication and initiating evidence-based medication treatment. Opioid withdrawal presents with dysphoria, myalgias, rhinorrhea, lacrimation, piloerection, nausea/vomiting/diarrhea, and autonomic hyperactivity, and while intensely uncomfortable, it is not life-threatening (unlike alcohol or benzodiazepine withdrawal, which can be fatal). First-line treatment for opioid use disorder is medication-assisted treatment with buprenorphine (a partial mu-opioid agonist) or methadone (a full agonist, typically dispensed through licensed opioid treatment programs), both of which reduce cravings, withdrawal, and overdose mortality risk; naltrexone (an opioid antagonist) is an alternative that requires roughly 7 to 10 days of confirmed abstinence before initiation to avoid precipitating withdrawal. Buprenorphine initiation itself requires the patient to be in at least mild-to-moderate objective withdrawal before dosing to avoid precipitated withdrawal, since administering a partial agonist to a patient with high levels of full agonist on board can displace the full agonist and abruptly precipitate severe withdrawal symptoms. Step 2 CK tests recognizing appropriate timing of buprenorphine induction relative to withdrawal severity and understanding that medication-assisted treatment, rather than abstinence-only detoxification, is the evidence-based standard of care for opioid use disorder.
Key terms
- Schizoaffective disorder
- — DSM-5-TR diagnosis requiring a concurrent major mood episode with schizophrenia-level psychosis, at least two weeks of psychotic symptoms without a mood episode at some point in the illness, and mood symptoms present for the majority of the total illness duration.
- Treatment-resistant schizophrenia
- — Inadequate response to adequate trials of at least two antipsychotics (adequate dose, duration, and confirmed adherence); the guideline-supported next step is clozapine with mandatory ANC monitoring.
- Clozapine agranulocytosis monitoring
- — Mandatory regular absolute neutrophil count monitoring required during clozapine treatment due to the risk of life-threatening agranulocytosis.
- Neuroleptic malignant syndrome
- — Antipsychotic-induced emergency with fever, rigidity, autonomic instability, and elevated creatine kinase; treated with drug discontinuation, cooling, and supportive care.
- Precipitated withdrawal
- — Abrupt, severe opioid withdrawal triggered when buprenorphine is given too early (before adequate withdrawal has developed) in a patient with full opioid agonist still active.
- Medication-assisted treatment (MAT)
- — Evidence-based treatment for opioid use disorder using buprenorphine, methadone, or naltrexone rather than abstinence-only detoxification.
- Means restriction
- — A concrete suicide-prevention intervention involving removing or securing access to lethal means (e.g., firearms) in an at-risk patient's environment.
- Schizophreniform disorder
- — Diagnosis identical to schizophrenia in symptom criteria but with total illness duration of one to six months, distinguishing it from schizophrenia (six months or more).
Exam tips
- Track the exact timeline in mood/psychosis vignettes: psychotic symptoms occurring only during mood episodes points away from schizoaffective disorder and toward a mood disorder with psychotic features.
- Treatment resistance means failure of at least two adequate, adherence-confirmed antipsychotic trials — a single failed or non-adherent trial is a distractor, not a true indication for clozapine.
- Always ask directly about suicidal plan, intent, and access to means in any at-risk stem; failing to assess is itself commonly the tested error.
- For buprenorphine induction questions, confirm the patient is already in objective withdrawal before dosing — starting too early risks precipitated withdrawal.
- Distinguish opioid withdrawal (miserable but not lethal) from alcohol/benzodiazepine withdrawal (potentially fatal) when a vignette asks about urgency of treatment.
- Recognize NMS from the fever-rigidity-autonomic instability-elevated CK tetrad and choose stopping the offending agent plus supportive care, not simply switching antipsychotics.